Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2007

View Archived Issues

Novel anticancer drugs disclosed in recent patent literature

Updated findings for Genentech oncology candidates

Phase II study shows tipifarnib is active in relapsed/refractory acute myeloid leukemia

Novel formalin-inactivated vaccine protects against Ross River virus infection in preclinical tests

Purinergic P2X3/P2X2/3 receptor blockade attenuates cold and mechanical allodynia in rat pain models

Interim analysis planned for BiovaxID phase III trial

Biovitrum's novel tyrosine kinase inhibitor shows preclinical activity against AML

Recent patents describe new treatment options for cardiovascular diseases

Pharmacopeia achieves milestone in GSK collaboration

SEC declares effective Valentis and Urigen merger

ViroPharma makes progress in phase II clinical program for HCV-796

New therapeutic agents for sleep disorders, depression and schizophrenia reported in recent patents

Sciele Pharma acquires Alliant Pharmaceuticals

Axcan initiates phase III trial of MAX-002 for ulcerative proctitis

Barrier reports results from phase II/III liarozole trial

Urigen assigns collaborative consultant for URG-301 program

Pluristem's PLX cells show potential for Parkinson's disease

Intermezzo effective in treating middle of the night awakening

Y-320: novel antiarthritic drug profiled at Mitsubishi Pharma

CAT-3888 shows activity in phase I and II trials in leukemia patients

A phase I study of SSR-244738 in patients with refractory solid tumors

Japanese launch for once-weekly Benet

Encouraging results with targeted radiotherapy in advanced lung cancer patients

Ceftobiprole submitted for cSSTI in E.U.

Third approvable letter for Thelin

FDA approval for Letairis for PAH

Inovelon launched in Germany for Lennox-Gastaut syndrome